Immunic CEO Dr Daniel Vitt provides hope for sufferers during Celiac Awareness Month
#115: Daniel Vitt - The Future of Biotech: Immunic Therapeutics’ Visionary Approach
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Daniel Vitt - Immunic’s Quest for Next-Gen Autoimmune Treatments
Immunic CEO Daniel Vitt discusses rise in autoimmune diseases and MS treatments
Daniel Vitt: Munich's Biotech Surge: The Untold Story Behind Europe's Innovation Hub
Is This the Penny Stock We Should All Buy Now? | DR. Daniel Vitt - IMUX CEO
Immunic CEO discusses Q2 results & MS trials update
Immunic gets a "positive surprise" from lead asset trial
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies
Immunic Inc eyeing "big step" for multiple sclerosis patients
Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis
Immunic "super excited" about latest PMS trial data
Immunic MS RnD Day New York City Recording
Nr. 1 der absolut beste Weg, um Ihre SCHILDDRÜSE ZU HEILEN
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic reports successful 2023 and prepares for key 2025 milestones
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
